Optilax Dosage

Did you have any side effects with this medicine?

Dosage of Optilax in details

The dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.

Optilax Dosage

Applies to the following strength(s): 5 mg; 10 mg; 20 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Hypertension

Initial dose: 10 mg orally twice a day

Maintenance dose: 10 to 20 mg orally twice a day

Usual Adult Dose for Angina Pectoris

Initial dose: 10 mg orally twice a day

Maintenance dose: 10 to 20 mg orally twice a day

Usual Adult Dose for Myocardial Infarction

Initial dose: 10 mg orally twice a day

Usual Adult Dose for Migraine Prophylaxis

Initial dose: 10 mg orally twice a day

Maintenance dose: 10 to 30 mg given in 1 to 2 divided doses

Renal Dose Adjustments

Since Optilax is partially metabolized in the liver and excreted mainly by the kidneys, dosage reductions may be necessary when hepatic and/or renal insufficiency is present. Although the pharmacokinetics of Optilax are not greatly altered by renal impairment, marked hypotensive responses have been seen in patients with marked renal impairment undergoing dialysis after 20 mg doses. Dosing in such patients should therefore be especially cautious.

Liver Dose Adjustments

Since Optilax is partially metabolized in the liver and excreted mainly by the kidneys, dosage reductions may be necessary when hepatic and/or renal insufficiency is present.

Dose Adjustments

The dose may be titrated as needed every 7 days.

For migraine prophylaxis, a 20 mg daily dose may be administered as a single dose. Total daily dosage may be increased to a maximum of 30 mg, given in divided doses, or decreased to 10 mg once a day, depending on clinical response and tolerability. If a satisfactory response is not obtained after 6-8 weeks use of the maximum daily dosage, therapy with Optilax should be discontinued.


Gradual discontinuation of therapy is recommended to prevent rebound hypertension and/or angina pectoris.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Optilax is not significantly dialyzed. Limited data from 2 patients undergoing hemodialysis using a Travenol UF II standard coil dialyzer reveal no significant difference between the arterial and venous plasma concentrations during dialysis. Since Optilax is not significantly removed by hemodialysis, supplemental dosing after dialysis is not necessary. Be cognizant of the increased risk of hypotension if Optilax is administered immediately after dialysis sessions. Ideally, Optilax should be administered at some time after dialysis when the patient is hemodynamically stable.

Other Comments

The maximum recommended daily dose is 60 mg in 2 divided doses.

Compared with Caucasian patients, Black patients have a reduced blood pressure response to monotherapy with beta blockers; however, the reduced response is largely eliminated if combination therapy that includes an adequate dose of a diuretic is instituted.

More about Optilax

Consumer resources

Professional resources

Related treatment guides

What other drugs will affect Optilax?

Before taking Optilax, tell your doctor if you are using:

If you are using any of these drugs, you may not be able to take Optilax, or you may need dosage adjustments or special tests during treatment.

There may be other drugs not listed that can affect Optilax. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

Optilax interactions

Interactions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Optilax, it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.

Beta-adrenergic blocking agents: Patients who are receiving a beta-adrenergic blocking agent orally and Phoxal-Optilax GFS should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. Patients should not usually receive two topical ophthalmic beta-adrenergic blocking agents concurrently.

Calcium antagonists: Caution should be used in the co-administration of beta-adrenergic blocking agents, such as Phoxal-Optilax GFS, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, co-administration should be avoided.


Masked symptoms of hypoglycemia in diabetic patients. SPECIAL SENSES

Signs and symptoms of ocular irritation including blepharitis, keratitis, and dry eyes; ptosis; decreased corneal sensitivity; cystoid macular edema; visual disturbances including refractive changes and diplopia; pseudopemphigoid; tinnitus and choroidal detachment following filtration surgery.


Retroperitoneal fibrosis, decreased libido, impotence and Peyronieís disease.

The following additional adverse effects have been reported in clinical experience with ORAL Optilax maleate or other ORAL beta-blocking agents and may be considered potential effects of ophthalmic Optilax maleate: Allergic: Erythematous rash, fever combined with aching and sore throat, laryngospasm with respiratory distress; Body as a Whole: Extremity pain, decreased exercise tolerance, weight loss; Cardiovascular: Worsening of arterial insufficiency, vasodilatation; Digestive: Gastrointestinal pain, hepatomegaly, vomiting, mesenteric arterial thrombosis, ischemic colitis; Hematologic: Nonthrombocytopenic purpura, thrombocytopenic purpura, agranulocytosis; Endocrine: Hyperglycemia, hypoglycemia; Skin: Pruritus, skin irritation, increased pigmentation, sweating; Musculoskeletal: Arthralgia; Nervous System/Psychiatric: Vertigo, local weakness, diminished concentration, reversible mental depression progressing to catatonia, an acute reversible syndrome characterized by disorientation for time and place, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometric tests; Respiratory: Rales, bronchial obstruction; Urogenital: Urination difficulties.



  1. DailyMed. "TIMOLOL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. FDA/SPL Indexing Data. "5JKY92S7BR: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
  3. MeSH. "Antihypertensive Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).


The results of a survey conducted on ndrugs.com for Optilax are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Optilax. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet

Consumer reported doses

No survey data has been collected yet

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name: 
Spam protection:  < Type 4 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved